Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
10 p, 538.1 KB Acute respiratory distress syndrome subphenotypes and therapy responsive traits among preclinical models : protocol for a systematic review and meta-analysis / Carla, Adrien (CHU Clermont-Ferrand) ; Pereira, Bruno (CHU Clermont-Ferrand) ; Boukail, Hanifa (CHU Clermont-Ferrand) ; Audard, Jules (Université Clermont Auvergne) ; Pinol-Domenech, Nathalie (Université Clermont Auvergne) ; De Carvalho, Manuela (Université Clermont Auvergne) ; Blondonnet, Raiko (Université Clermont Auvergne) ; Zhai, Ruoyang (Université Clermont Auvergne. GReD) ; Morand, Dominique (CHU Clermont-Ferrand) ; Lambert, Céline (CHU Clermont-Ferrand) ; Sapin, Vincent (CHU Clermont-Ferrand) ; Ware, Lorraine B. (Vanderbilt University Medical Center) ; Calfee, Carolyn S. (University of California San Francisco) ; Bastarache, Julie A. (Vanderbilt University) ; Laffey, John (National University of Ireland Galway) ; Juffermans, Nicole P. (Amsterdam UMC. University Medical Center) ; Bos, Lieuwe D.. (University Medical Center) ; Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Rocco, Patricia R. M. (Federal University of Rio de Janeiro) ; Matthay, Michael A. (University of California San Francisco) ; McAuley, Daniel F. (Queens University Belfast) ; Constantin, Jean-Michel (Sorbonne University) ; Jabaudon, Matthieu (Vanderbilt University Medical Center) ; Universitat Autònoma de Barcelona
Subphenotypes were recently reported within clinical acute respiratory distress syndrome (ARDS), with distinct outcomes and therapeutic responses. Experimental models have long been used to mimic features of ARDS pathophysiology, but the presence of distinct subphenotypes among preclinical ARDS remains unknown. [...]
2020 - 10.1186/s12931-020-01337-9
Respiratory Research, Vol. 21 (april 2020)  
2.
9 p, 426.8 KB Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A : Final Results of the NuProtect Study / Liesner, Ri J. (Great Ormond Street Hospital for Children (Londres)) ; Abraham, Aby (Christian Medical College (Vellore, India). Department of Hematology) ; Altisent, Carmen (Hospital Universitari Vall d'Hebron) ; Belletrutti, Mark J. (University of Alberta. Department of Pediatrics) ; Carcao, Manuel (Hospital for Sick Children (Toronto, Canada). Department of Paediatrics) ; Carvalho, Manuela (São João University Hospital Centre (Porto, Portugal)) ; Chambost, Hervé (Aix Marseille University. Department of Pediatric Hematology Oncology) ; Chan, Anthony K. C. (McMaster University. Division of Pediatric Hematology/Oncology) ; Dubey, Leonid (Western Ukrainian Specialized Children's Medical Centre. Department of Pediatrics) ; Ducore, Jonathan (University of California Davis Medical Center. Department of Pediatrics) ; Gattens, Michael (Cambridge University Hospitals NHS Foundation Trust (Regne Unit)) ; Gresele, Paolo (University of Perugia. Department of Medicine and Surgery) ; Gruel, Yves (Hôpital Trousseau (Tours, França)) ; Guillet, Benoit (Univ Rennes. Haemophilia Treatment Centre) ; Jimenez-Yuste, Victor (Hospital Universitario La Paz (Madrid)) ; Kitanovski, Lidija (University Medical Center Ljubljana. Department of Haemato-Oncology) ; Klukowska, Anna (Warsaw Medical University. Department of Pediatrics, Haematology and Oncology) ; Lohade, Sunil (Sahyadri Speciality Hospital. Department of Hematology) ; Mancuso, Maria Elisa (Humanitas Clinical and Research Center) ; Oldenburg, Johannes (University Clinic Bonn. Institute of Experimental Haematology and Transfusion Medicine) ; Pavlova, Anna (University Clinic Bonn. Institute of Experimental Haematology and Transfusion Medicine) ; Pollio, Berardino (Regina Margherita Children Hospital of Turin. Department of Transfusion Medicine) ; Sigaud, Marianne (CHU de Nantes) ; Vdovin, Vladimir (Morozovskaya Children's Hospital. Department of Hematology) ; Vilchevska, Kateryna (Institute of Urgent and Reconstructive Surgery named after V.K. Gusak of National Academy of Medical Sciences of Ukraine.Department of Hematology) ; Wu, John K. M. (British Columbia Children's Hospital (Vancouver, Canadà)) ; Jansen, Martina (Octapharma Pharmazeutika Produktionsges.mbH) ; Belyanskaya, Larisa (Octapharma AG) ; Walter, Olaf (Octapharma AG) ; Knaub, Sigurd (Octapharma AG) ; Neufeld, Ellis J. (St. Jude Children's Research Hospital (Memphis, Estats Units d'Amèrica))
Introduction FVIII inhibitor development is the most serious contemporary treatment complication in haemophilia A, particularly in previously untreated patients (PUPs). No inhibitors developed in clinical trials in previously treated patients treated with simoctocog alfa (Nuwiq), a fourth-generation recombinant FVIII produced in a human cell line. [...]
2021 - 10.1055/s-0040-1722623
Thrombosis and Haemostasis, Vol. 121 Núm. 11 (february 2021) , p. 1400-1408  

Vegeu també: autors amb noms similars
1 Carvalho, M.
1 Carvalho, M. Fernanda N.N.
1 Carvalho, M. H. C.
1 Carvalho, Marco Antônio de
1 Carvalho, Maria
1 Carvalho, Maria João P. M.
1 Carvalho, Maria Raquel S.
1 Carvalho, Monica
1 Carvalho, Mónica R.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.